BioSight
Companies
ARGENX SE logo

ARGX

NASDAQZWIJNAARDE
ARGENX SE

Argenx SE is a commercial-stage immunology company developing monoclonal antibodies for rare autoimmune diseases. Its lead approved product, VYVGART (efgartigimod alfa-fcab), is available intravenously and subcutaneously for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, with additional approvals in Japan for immune thrombocytopenia. The company markets VYVGART under regional brand names including VYVGART HYTRULO in the U.S. and China, and VYVDURA in Japan.

$781.72+21.17%1Y
ARGX · daily close · illustrative · 0 catalysts marked
$493$612$731$850$969Apr '25Aug '25Dec '25Apr '26
1Y high$929.611Y low$532.27range$397.34(75%)past catalysts

Pipeline10

Efgartigimod IV
Phase 2/3Generalized Myasthenia Gravis
Phase 3Generalized Myasthenia Gravis
Phase 2/3Immune Thrombocytopenia
Phase 3Immune Thrombocytopenia
Phase 2Generalized Myasthenia Gravis
small-molecule
Efgartigimod PH20 SC
Phase 3Immune Thrombocytopenia
Phase 2/3Generalized Myasthenia Gravis
Phase 3Primary Sjogren's Disease
Phase 2Chronic Inflammatory Demyelinating Polyneuropathy
small-molecule
empasiprubart
Phase 3Chronic Inflammatory Demyelinating Polyneuropathy
Phase 3Multifocal Motor Neuropathy
small-molecule
Empasiprubart IV
Phase 2Dermatomyositis
Phase 2Myositis
Phase 3Chronic Inflammatory Demyelinating Polyneuropathy
Phase 2Generalized Myasthenia Gravis
small-molecule
IVIg
Phase 3Chronic Inflammatory Demyelinating Polyneuropathy
small-molecule
IVIG (Intravenous Immunoglobulin)
Phase 3Multifocal Motor Neuropathy
small-molecule
EFG PH20 SC
Phase 2/3Dermatomyositis
Phase 2/3Myositis
small-molecule
ARGX-117
Phase 2Delayed Graft Function
Phase 2Multifocal Motor Neuropathy
small-molecule
ARGX-119
Phase 2Amyotrophic Lateral Sclerosis
small-molecule
ARGX-119 IV
Phase 2Spinal Muscular Atrophy
small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar